[City, Country] – [Date] – In a significant stride forward for cardiovascular medicine, Abbott has unveiled promising long-term data for its investigational TactiFlex Duo ablation catheter, a device designed to offer unprecedented flexibility and efficacy in treating atrial fibrillation (AFib). The dual-technology catheter, which combines both pulsed-field ablation (PFA) and radiofrequency (RF) ablation, has demonstrated robust safety and effectiveness at 12 months in the FlexPulse investigational device exemption (IDE) study, further solidifying its potential to reshape the landscape of AFib management.
n
The latest findings, presented at the prestigious 2026 European Society of Cardiology (ESC) congress in Munich, Germany, build upon earlier six-month clinical outcomes and indicate a substantial improvement in patient outcomes. This innovative approach from Abbott equips electrophysiologists with a versatile tool to tailor treatments to individual patient needs, a critical advancement in addressing a condition that affects millions worldwide and is projected to significantly increase in prevalence.
n
Pioneering Dual-Technology for Atrial Fibrillation
n
Atrial fibrillation, a common heart rhythm disorder, is characterized by irregular and often rapid heartbeats. If left untreated, AFib can lead to serious complications such as stroke, heart failure, and other heart-related problems. Catheter ablation has emerged as a cornerstone therapy, aiming to restore a normal heart rhythm by creating scar tissue in specific areas of the heart that trigger or sustain AFib.
n
Traditionally, catheter ablation has relied on either radiofrequency (RF) energy, which uses heat to create lesions, or cryoablation, which uses cold. Abbott’s TactiFlex Duo introduces a groundbreaking dual-technology approach, integrating both PFA and RF ablation capabilities within a single catheter. This fusion of technologies offers physicians a crucial advantage: the ability to choose the most appropriate ablation modality for each patient and each specific lesion target, thereby optimizing treatment efficacy and safety.
n
Pulsed-field ablation (PFA) is a newer, non-thermal energy source that ablates cardiac tissue by delivering short electrical pulses. Its key advantage lies in its high selectivity, primarily targeting cardiac muscle cells while sparing surrounding critical structures like the esophagus, phrenic nerve, and pulmonary veins. Radiofrequency (RF) ablation, on the other hand, has been the gold standard for decades, offering precise lesion creation and durability. By combining these two distinct energy sources, the TactiFlex Duo aims to leverage the strengths of each, providing a more comprehensive and adaptable treatment solution.
n
Chronology of Innovation: From Concept to Clinical Validation
n
The development of TactiFlex Duo represents a strategic evolution of Abbott’s commitment to advancing cardiac rhythm management. The catheter builds upon the foundation of Abbott’s TactiFlex AF, a radiofrequency ablation-only catheter that received U.S. Food and Drug Administration (FDA) clearance in May 2023. This prior success paved the way for further innovation, leading to the development of the dual-technology TactiFlex Duo.
n
The journey of TactiFlex Duo has been meticulously documented through clinical trials, culminating in the recent presentation of 12-month data from the FlexPulse IDE study. This study, designed to gather comprehensive safety and effectiveness data for regulatory submission, has been instrumental in validating the device’s performance.
n
Key milestones include:
n
- n
- May 2023: Abbott’s TactiFlex AF, a radiofrequency ablation-only catheter, receives FDA clearance, marking a significant step in the company’s AFib ablation portfolio.
- January 2026: The TactiFlex Duo dual ablation catheter achieves European CE Mark approval, signaling its readiness for broader clinical adoption in Europe.
- 2026 ESC Congress: Presentation of 12-month results from the FlexPulse IDE study, showcasing the long-term safety and effectiveness of TactiFlex Duo in treating AFib.
- Simultaneous Publication: The detailed findings of the FlexPulse study are published in EP Europace, a leading peer-reviewed journal in the field of cardiac electrophysiology, providing independent scientific validation of the results.
n
n
n
n
n
This progressive timeline highlights Abbott’s dedication to rigorous clinical evaluation and its strategic approach to bringing advanced medical technologies to market.
n
Supporting Data: Robust Evidence of Efficacy and Safety
n
The 12-month findings from the FlexPulse IDE study provide compelling evidence of TactiFlex Duo’s efficacy in managing atrial fibrillation. The study met its primary effectiveness endpoint, demonstrating that a significant proportion of patients remained free from documented arrhythmias, medication adjustments, or repeat procedures.
n
Key Efficacy Data at 12 Months:
n
- n
- Primary Effectiveness Endpoint: 74.6% of patients remained free from documented arrhythmias, medication changes, or repeat procedures. This metric is crucial as it reflects sustained freedom from AFib and the need for further intervention.
- Recurrence of Atrial Arrhythmias (Standard of Care Monitoring): 92.6% of patients experienced no documented recurrence of AFib, atrial flutter, or atrial tachycardia during the 12-month follow-up when assessed using standard of care (SoC) monitoring. This indicates a high success rate in eliminating problematic heart rhythms.
- Recurrence of Atrial Arrhythmias (Protocol-Driven Monitoring): 77.4% of patients experienced no documented recurrence of AFib, atrial flutter, or atrial tachycardia during follow-up when assessed using more intensive, protocol-driven monitoring. While this figure is lower than with SoC monitoring, it still represents a substantial success rate and provides a more precise measure of the therapy’s effectiveness.
n
n
n
n
These results not only reinforce the positive outcomes observed in the earlier six-month data but also provide crucial reassurance regarding the durability of the treatment’s effects over a longer period. The ability to achieve such high rates of freedom from recurrence is a testament to the combined power of PFA and RF ablation technologies, offering physicians a more reliable and effective means to restore and maintain normal sinus rhythm.
n
The study’s design, incorporating both standard and protocol-driven monitoring, offers a comprehensive view of the device’s performance. While SoC monitoring reflects real-world clinical practice, protocol-driven monitoring provides a more granular assessment of potential subclinical recurrences, offering deeper insights into the long-term efficacy. The consistently positive results across both monitoring methods underscore the robust nature of the TactiFlex Duo’s therapeutic impact.
n
Official Responses and Expert Endorsements
n
The unveiling of the TactiFlex Duo’s long-term data has garnered significant attention from the medical community. Experts in the field have expressed optimism about the device’s potential to enhance patient care.
n
Dr. Ayman Hussein, Director of Cardiac Electrophysiology Research at Cleveland Clinic, who presented the FlexPulse IDE data at the ESC congress, highlighted the importance of such advanced technologies. "As physicians, we’re looking for technologies that help us confidently deliver the best possible outcomes for our patients, not just at the time of the procedure, but for years afterward," Dr. Hussein stated. "The evidence behind this device helps increase confidence in ablation therapy and hopefully support lasting outcomes for patients with atrial fibrillation."
This endorsement from a leading electrophysiology researcher underscores the clinical significance of the TactiFlex Duo. The ability to provide physicians with greater confidence in achieving durable, long-term results is paramount in the management of chronic conditions like AFib. The dual-technology approach, by offering adaptability, is seen as a key factor in achieving these improved outcomes.
Abbott’s commitment to developing innovative solutions for AFib is further evidenced by its proactive engagement with emerging technologies. While TactiFlex Duo is currently investigational in the US, its CE Mark in Europe signifies a significant step towards broader accessibility. Abbott has also demonstrated its commitment to the PFA space with its Volt system, which received a European CE Mark in March 2025 for treating AFib patients. This dual focus on both established RF technology and cutting-edge PFA, integrated into a single device, positions Abbott at the forefront of AFib treatment innovation.
Implications for the Future of AFib Management
The advent of the TactiFlex Duo has profound implications for the future of atrial fibrillation treatment. Its dual-technology design promises to address several key challenges in current AFib ablation procedures.
Firstly, the flexibility offered by the combination of PFA and RF ablation allows physicians to tailor treatment strategies to the unique anatomy and rhythm characteristics of each patient. In cases where precise, deep lesions are required, RF energy can be employed. For more superficial or challenging lesions, or when proximity to critical structures is a concern, the selective, non-thermal nature of PFA can be advantageous. This personalized approach has the potential to improve procedural success rates and reduce the likelihood of complications.
Secondly, the positive long-term efficacy data suggests that TactiFlex Duo may lead to more durable and sustained freedom from AFib. This could translate into a reduced need for repeat procedures, fewer medication adjustments, and ultimately, a higher quality of life for patients. For individuals living with AFib, the prospect of a single procedure that offers a greater chance of long-term rhythm control is incredibly appealing.
The growing global prevalence of AFib, with projections indicating a doubling of affected individuals by 2050, underscores the urgent need for effective and scalable treatment solutions. Abbott’s TactiFlex Duo appears well-positioned to meet this escalating demand. The global electrophysiology devices market, which includes ablation catheters, is experiencing robust growth, projected to reach nearly $25 billion by 2035. Innovations like TactiFlex Duo are key drivers of this market expansion, offering advanced solutions that improve patient care and address unmet clinical needs.
Furthermore, the availability of a device that combines two distinct energy modalities may simplify workflow for electrophysiologists, potentially reducing procedure times and improving overall efficiency in the electrophysiology lab. As the technology gains wider adoption and regulatory approvals, it could become a standard of care for a broad spectrum of AFib patients, from those with paroxysmal AFib to those with persistent forms of the condition.
In conclusion, Abbott’s TactiFlex Duo represents a significant leap forward in the fight against atrial fibrillation. The promising 12-month data from the FlexPulse study, coupled with the device’s innovative dual-technology design, positions it as a potentially transformative tool for electrophysiologists and a beacon of hope for millions of patients worldwide seeking lasting relief from this debilitating heart rhythm disorder. As the device progresses through regulatory pathways, its impact on AFib management is anticipated to be substantial, ushering in an era of more personalized, effective, and durable cardiac ablation therapies.
